Joslin Diabetes Center Primary Care Congress for Cardiometabolic Health 2013 Coronary Artery Disease in Women: Clinical Perspectives
|
|
- Francis Bryan
- 5 years ago
- Views:
Transcription
1 Primary Care Congress for Cardiometabolic Health 213 Coronary Artery Disease in : Clinical Perspectives JoAnn E. anson, D, DrPH, AHA Chief, Division of Preventive edicine Brigham and 's Hospital Professor of edicine and the ichael and Lee Bell Professor of 's Health Harvard edical School Conflict of Interest Disclosure JoAnn E. anson, D, DrPH, has no real or apparent conflicts of interest to report. Cardiometabolic Congress Boston, assachusetts April 24, 213 Objectives To describe the major risk factors for CVD in women. To review key gender differences in risk factors. To summarize changes in risk factors during the life cycle, especially at the menopause transition. To review (briefly) clinical trial findings on menopausal hormone therapy, aspirin, and calcium/vitamin D. Cardiovascular Disease: The Leading Cause of Death in US (26 data) Heart disease Cerebrovascular disease Lung cancer COPD Unintentional Injuries Breast Cancer Diabetes Influenza/Pneumonia otor vehicle Accidents Deaths (1,) National Center for Health Statistics. Health, United States, 29: With Special eature on edical Technology. Hyattsville, D. 21. Prevalence of CVD by Age and Sex ale emale Percent of Population NHANES III Copyright 213 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any 1
2 Primary Care Congress for Cardiometabolic Health 213 Nurses' Health Study: Preventability of Heart Disease, Stroke, and Type 2 Diabetes Percentage of US Adults Classified as Obese (BI >3) in Health Surveys from With lifestyle modifications*: 4 CHD Stroke Diabetes 35 3 en Risk Reduction (%) NEJ 2; 343:16-22; NEJ 21; 345: % -81% -9% * Physical activity, not smoking, weight control, healthy diet (high in whole grains, fiber, fruit/veg, fish, low in saturated fat) NHES I NHANES I NHANES II NHANES III NHANES NHANES NHANES NHANES (1963-7) ( ) (1976-8) ( ) ( ) (23-4) (27-8) (29-1) NHES indicates National Health Examination Survey; NHANES, National Health and Nutrition Examination Survey. Sources: legal K, et al. JAA 22; 288:1723-7; JAA 26; 295: ; JAA 21; 33:235-41; JAA 212; 37: Percent of U.S. adults Engaging in Regular Leisure-time Physical Activity,* by Gender and Age 5 4 en * Regular activity = light-to-moderate activity >5 times/week for 3 minutes each time, or vigorous activity >3 times/week for >2 minutes each time. Reference: Schoenborn CA, Barnes P. Leisure-time physical activity among adults: United States, NCHS, 22. Percentage of the Decrease in U.S. Deaths from CHD Attributed to Treatments and Risk-actor Changes The Interheart Study Treatment Risk actors Unexplained Case-control study of 15, patients with first I compared to 15, age, sex matched healthy controls Source: ord ES et al. N Engl J ed 27; 356: Source: Yusuf. Lancet 24. Copyright 213 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any 2
3 Primary Care Congress for Cardiometabolic Health 213 INTERHEART: Association of Risk actors with Acute I in And en Lifetime Risk for CVD by Risk actors at Age 5 Risk actor Gender Odds Ratio (99% CI) Current smoking Diabetes Hypertension Abdominal obesity Psychosocial index ruits/vegetables Exercise Alcohol ApoB-ApoA1 ratio Adjusted for age, sex, geographic region Note: odds ratio plotted on a doubling scale Source: Yusuf S et al. Lancet. 24;364: Adjusted Cumulative Incidence en Source: Lloyd-Jones, Circulation % 5%.7.6 5% 5%.5 46%.4 39% 36%.3 27%.2.1 Attained Age 2 ajor Rs 1 ajor R 1 Elevated R 1 Not Optimal R Optimal Rs % SWAN Allows Us to Anchor Our Observations to the inal enstrual Period (P). A Steep Rise In LDL Occurs within One Year of the P Source: atthews JACC 29; 54:2366. % of ean Level During Premenopause % of ean Level During Premenopause Total-C LDL-C enopause Source: Jensen et al. aturitas 199; 12: Change in Lipids After enopause N=1 onths HDL-C enopause Triglycerides onths SWAN Shows A Rise In at ass With The P SWAN: Progression of Subclinical CVD During Late Perimenopause Annual Rates of Change in Carotid IT in Pre, Early peri, Late peri, and Postmenopausal stages*.25 a,b.2 IT progression rate (mm/year) Premenopause Early perimenopause Late perimenopause Postmenopause * Adjusted for age at baseline and race a Rate of change in late peri significantly differs from that in premenopausal stage, P<.5 b Rate of change in late peri significantly differs from that in early peri menopausal stage, P.5 Source: Sowers et al. JCE 27; 92: El Khoudary SR, Wildman RP, atthews KA, Thurston RC, Bromberger JT, Sutton Tyrrell K. enopause In Press Copyright 213 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any 3
4 Primary Care Congress for Cardiometabolic Health Diabetes and Risk of CHD ortality en Diabetic en fold risk Diabetic fold risk Lipid Lowering and CHD Risk Reduction in Diabetes Scandinavian Simvastatin Survival Study (4S): 54% reduction in CHD events in D subjects randomized to simvastatin vs. controls (32% risk reduction in nondiabetic subjects). All cause mortality: reduction of 43% for D subjects and 28% for non-d. CARE Study (Pravastatin after I in subjects with average cholesterol levels): 25% reduction in CHD among D subjects and 23% reduction in non-d. Helsinki Heart Study (Gemfibrozil) Similar risk reductions in } ACAPS/TexCAPS (Lovastatin) D and non-d United Kingdom Prospective Diabetes Study (UKPDS) Predictors of irst Coronary Events 1) LDL cholesterol <.1 2) HDL cholesterol <.1 3) HbA1c.2 4) Systolic BP.6 5) Smoking.56 Pregnancy: A Stress Test for the Cardiovascular System Pregnancy: metabolic syndrome-like state. predisposed to etsyn develop gestational hypertension or gestational diabetes. Pregnancy induced risk factors often re-emerge later in life. ortality from CVD in later life is increased by these conditions fold higher mortality in women who had a preterm delivery and pre-eclampsia. Source: Stratton et al. BJ 2; 321:45-12 Current Opinion in Obstetrics and Gynecology 23, 15: Lipids and Coronary Heat Disease (CHD): Gender Differences Effects on major Vascular Events per 1. mmol/l Reduction in LDL Cholesterol at Different Levels of Risk, by Gender 5-year VE Risk Events (% per annum) Trend at Baseline Statin/more Control/less Test RR (CI) per 1. mmol/l reduction in LDL cholesterol LDL cholesterol: HDL cholesterol: Triglycerides: Stronger predictor of CHD risk in men than women Stronger predictor of CHD risk in women than men Stronger predictor of CHD risk in women than men Source: Cholesterol Treatment Trialists Collaborators. Lancet 212; 38(9841) supplementary appendix. Copyright 213 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any 4
5 Primary Care Congress for Cardiometabolic Health 213 Risk of Heart Attack: Smokers vs Ex-smokers Relative Risk Estimate* AHA Guidelines Current Smokers ales emales Ex-smokers Effectiveness-Based Guidelines for the Prevention of Cardiovascular Disease in 211 Update: A guideline from the American Heart Association Years Since Quitting osca L, Benjamin EJ, Berra K, et al. J Am Coll Cardiol 211;57: and Circulation 211;123: * 1. represents no increased risk compared with lifetime nonsmokers. Source: Rosenberg NEJ; 1985 & 199. Ideal Cardiovascular Health (all are required!) Total cholesterol < 2 mg/dl (untreated) BP < 12/8 mmhg (untreated) asting blood glucose < 1 mg/dl (untreated) Body mass index < 25 kg/m2 Abstinence from smoking Physical activity at goal for adults > 2 years of age >15 min/week moderate intensity >75 min/week vigorous activity or combination Healthy diet (DASH or similar) But fewer than 4% of women meet these criteria! WHI Estrogen+Progestin Trial indings, July 22 (mean follow-up 5.2 yrs) Risks Coronary Heart Disease 29% Stroke 41% Pulmonary Embolism 113% Breast Cancer 26% STOPPED Early, Clear Harm Stopped 3.3 years early Adapted from: Writing Group for the s Health Initiative. JAA 22;288: Benefits Hip racture 34% Colorectal Cancer 34% Threshold Level WHI Estrogen-Alone and Health Outcomes (N=1,739; mean age 63.6 yrs; mean follow-up 6.8 yrs) Relative Risks and 95% CI* for Selected Health Outcomes by Years Since enopause in the WHI Trials of Hormone Therapy (E+P and E-Alone) Risks Stroke 39% Null CHD (.91) Pulm Emb (1.34) Breast Cancer (.77) Colorectal Cancer (1.8) Total ortality (1.4) Global Index (1.1) Benefits Hip racture 39% By years since menopause: CHD <1 y 1-19 y 2+ y Total mortality <1 y 1-19 y 2+ y Global index <1 y 1-19 y 2+ y p=.2 p=ns p=ns STOPPED Early Source: JAA 24; 291: Stopped 1 year early Threshold Level * Confidence intervals plotted as error bars. p values for trend. The global index is a composite outcome of CHD, stroke, PE, breast cancer, colorectal cancer, endometrial cancer (estrogen+progestin trial only), hip fracture, and mortality. Source: Rossouw JE, et al. JAA 27;297: Copyright 213 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any 5
6 Primary Care Congress for Cardiometabolic Health 213 Hormone Therapy (HT) Decision-aking lowchart CHD Risk Over 1 Years (ramingham CHD Risk Score) Significant symptoms of menopause (moderate-to-severe hot flashes, night sweats)? No Assess CHD risk and years since last menstrual period Years Since Last enstrual Period <5 6 to 1 >1 Very low (<5%) HT OK HT OK Low (5% to <1%) HT OK HT OK (Choose transdermal) oderate (1% to 2%) HT OK HT OK (Choose transdermal) (Choose transdermal) High (more than 2%) Yes ree of contraindications to HT and no h/o CHD, stroke, or TIA? AND No increased risk of stroke (<1% by ramingham Stroke Score)? Yes DECISION ABOUT DURATION O USE: continued moderate-to-severe symptoms; patient preference; weigh baseline risks of breast cancer vs osteoporosis No Antiplatelet Therapy in Secondary Prevention of CVD Overview of 25 randomized trials (N=29,) Aspirin and/or dipyridamole or sulfinpyrazone 32% reduction in nonfatal I 27% reduction in nonfatal stroke 15% reduction in CVD mortality 25% reduction in total important vascular events Adapted from: J anson and S Bassuk. In: Harrison s Principles of Internal edicine 28 Low-Dose Aspirin in CVD Primary Prevention eta-analysis Aspirin and Primary Prevention of CVD in the WHS According to Age Group+ Infarction yocardial Stroke All Participants.76 (.62.95).97 ( ) (N=95,456) en.68 (.54.86) 1.13 ( ) (N=44,114).99 ( ).81 (.69.96) (N=51,342) Total CVD Stroke I >65 Age Group (years) P for interaction by age =.5 for total CVD and.3 for I + p for interaction not significant for ramingham CHD Risk Score or Number of CHD Risk actors Source: NEJ 25; 352: Source: NEJ 25; 352: Calcium and Vitamin D Supplements: Cardiovascular Events by Treatment Group Assignment Acknowledgments Calcium/ Vitamin D Placebo Hazard Ratio P (N=18,176) (N=18,16) (95% CI) Cases Cases yocardial infarction or CHD death ( ).5 Stroke ( ).51 CABG indicates coronary artery bypass grafting. PCI, percutaneous coronary intervention. Number of events do no add up to the totals for categories because some women had >1 event. Colleagues in the s Health Initiative, s Health Study, Nurses Health Study and other research studies. volunteers in research studies. RebeccaThurston, ScD irian Limacher, D Puja ehta, D Karol Watson, D Source: Hsia J, et al. Circulation 27. Copyright 213 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any 6
7 Primary Care Congress for Cardiometabolic Health 213 Conclusions There is the potential for greater progress in decreasing risk of cardiovascular disease in women. ore attention must be given to: Prevention (incl. behavioral changes) Early detection Aggressive risk factor modification and treatment Copyright 213 by Joslin Diabetes Center, Inc. All rights reserved. These materials may be used for personal use only. Any 7
Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal
Cardiovascular Disease Risk: Pre-, Peri-, andpost-menopausal JoAnn E. Manson, MD, DrPH, FAHA Chief, Division of Preventive Medicine Brigham and Women's Hospital Professor of Medicine i and dthe Michael
More informationKathryn M. Rexrode, MD, MPH. Assistant Professor. Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School
Update: Hormones and Cardiovascular Disease in Women Kathryn M. Rexrode, MD, MPH Assistant Professor Division of Preventive Medicine Brigham and Women s s Hospital Harvard Medical School Overview Review
More informationLessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice
Lessons from the WHI HT Trials: Evolving Data that Changed Clinical Practice JoAnn E. Manson, MD, DrPH, FACP Chief, Division of Preventive Medicine Interim Executive Director, Connors Center Brigham and
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationMisperceptions still exist that cardiovascular disease is not a real problem for women.
Management of Cardiovascular Risk Factors in the Cynthia A., MD University of California, San Diego ARHP 9/19/08 Disclosures Research support Wyeth, Lilly, Organon, Novo Nordisk, Pfizer Consultant fees
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationCardiovascular Complications of Diabetes
VBWG Cardiovascular Complications of Diabetes Nicola Abate, M.D., F.N.L.A. Professor and Chief Division of Endocrinology and Metabolism The University of Texas Medical Branch Galveston, Texas Coronary
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationImpact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C
Impact of Lifestyle Modification to Reduce Cardiovascular Disease Event Risk of High Risk Patients with Low Levels of HDL C Thomas P. Bersot, M.D., Ph.D. Gladstone Institute of Cardiovascular Disease University
More informationKnow Your Number Aggregate Report Single Analysis Compared to National Averages
Know Your Number Aggregate Report Single Analysis Compared to National s Client: Study Population: 2242 Population: 3,000 Date Range: 04/20/07-08/08/07 Version of Report: V6.2 Page 2 Study Population Demographics
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationHormone therapy. Dr. med. Frank Luzuy
Hormone therapy Dr. med. Frank Luzuy Reasons for Initiating/Continuing HT* Menopause-Related Symptoms Osteoporosis, Bone Loss, Fracture Prevention Doctor Prescribed It, Told Me to Take It Cardiovascular
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationCardiovascular Risk Reduction in Women
Cardiovascular Risk Reduction in Women Karol E. Watson, MD, PhD Assistant Professor of Medicine/ Division of Cardiology Co-director, UCLA Program in Preventive Cardiology Director, Women s Cardiovascular
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationCoronary Heart Disease in Women Go Red for Women
Coronary Heart Disease in Women Go Red for Women Dr Fiona Stewart Green Lane Cardiovascular Service and National Women s Health Auckland City Hospital Auckland Heart Group Women are Different from Men
More informationThe Heart of a Woman. Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine
The Heart of a Woman Karen E. Friday, M.D. Associate Professor of Medicine Section of Endocrinology Louisiana State University School of Medicine American Heart Association Women, Heart Disease and Stroke
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationPrimary and Secondary Prevention of Cardiovascular Disease. Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group
Primary and Secondary Prevention of Cardiovascular Disease Frank J. Green, M.D., F.A.C.C. St. Vincent Medical Group AHA Diet and Lifestyle Recommendations Balance calorie intake and physical activity to
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
1980 to 2000: Death rate fell from: 542.9 to 266.8 per 100K men 263.3 to 134.4 per 100K women 341,745 fewer deaths from CHD in 2000 Ford ES, NEJM, 2007 47% from CHD treatments, 44% from risk factor modification
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationCVD Risk Assessment. Michal Vrablík Charles University, Prague Czech Republic
CVD Risk Assessment Michal Vrablík Charles University, Prague Czech Republic What is Risk? A cumulative probability of an event, usually expressed as percentage e.g.: 5 CV events in 00 pts = 5% risk This
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More information2013 Hypertension Measure Group Patient Visit Form
Please complete the form below for 20 or more unique patients meeting patient sample criteria for the measure group for the current reporting year. A majority (11 or more) patients must be Medicare Part
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationThe Gender Divide Women, Men and Heart Disease February 2017
The Gender Divide Women, Men and Heart Disease February 2017 Nandita S. Scott, MD FACC Co-Director MGH Heart Center Corrigan Women s Heart Health Program Massachusetts General Hospital Heart Disease For
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More information7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)
University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More information2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary
2013 ACC/AHA Guidelines on the Assessment of Atherosclerotic Cardiovascular Risk: Overview and Commentary The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease Becky McKibben, MPH; Seth
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationPreventing Cardiovascular Disease Stroke Primary Prevention Guidelines. John Potter Professor Ageing & Stroke Medicine University of East Anglia
Preventing Cardiovascular Disease Stroke Primary Prevention Guidelines John Potter Professor Ageing & Stroke Medicine University of East Anglia Preventing Cardiovascular Disease Stroke Primary Prevention
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationDyslipidaemia. Is there any new information? Dr. A.R.M. Saifuddin Ekram
Dyslipidaemia Is there any new information? Dr. A.R.M. Saifuddin Ekram PhD,FACP,FCPS(Medicine) Professor(c.c.) & Head Department of Medicine Rajshahi Medical College Rajshahi-6000 New features of ATP III
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More information1. Which one of the following patients does not need to be screened for hyperlipidemia:
Questions: 1. Which one of the following patients does not need to be screened for hyperlipidemia: a) Diabetes mellitus b) Hypertension c) Family history of premature coronary disease (first degree relatives:
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationThe Metabolic Syndrome: Is It A Valid Concept? YES
The Metabolic Syndrome: Is It A Valid Concept? YES Congress on Diabetes and Cardiometabolic Health Boston, MA April 23, 2013 Edward S Horton, MD Joslin Diabetes Center Harvard Medical School Boston, MA
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More informationwell-targeted primary prevention of cardiovascular disease: an underused high-value intervention?
well-targeted primary prevention of cardiovascular disease: an underused high-value intervention? Rod Jackson University of Auckland, New Zealand October 2015 Lancet 1999; 353: 1547-57 Findings: Contribution
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationMenopausal hormone therapy currently has no evidence-based role for
IN PERSPECTIVE HT and CVD Prevention: From Myth to Reality Nanette K. Wenger, M.D. What the studies show, in a nutshell The impact on coronary prevention Alternative solutions Professor of Medicine (Cardiology),
More informationDiabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology
Diabetes and Cardiovascular Risk Management Denise M. Kolanczyk, PharmD, BCPS-AQ Cardiology Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More informationSupplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
More information40% minimum reduction from
160 Circulatory Disease Mortality Target: Death rates in England 1993-2006 Persons under 75 Death / 100,000 population A fall of 44% over 10 years 140 120 100 80 60 40 20 141.0 84.2 Immortality guaranteed
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationSugar-Loaded Beverages and the Impact on Cardiovascular Health. Christina M. Shay, PhD, MA
Sugar-Loaded Beverages and the Impact on Cardiovascular Health Christina M. Shay, PhD, MA 1 Presenter Disclosure Information Christina M. Shay, PhD, MA Sugar-Loaded Beverages and the Impact on Cardiovascular
More informationThe target blood pressure in patients with diabetes is <130 mm Hg
Controversies in hypertension, About Diabetes diabetes and and metabolic Cardiovascular syndrome Risk ESC annual congress August 29, 2011 The target blood pressure in patients with diabetes is
More informationNICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant
NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide Roadmap Background
More informationRotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?
Disclosure Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause? Fractyl laboratories, Inc Anuja Dokras, MD., Ph.D. Professor of Obstetrics and Gynecology Director PENN PCOS
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationDisclosures. Overview 9/30/ ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults 2014 AAHP Fall Seminar Sherry Myatt, PharmD, BCPS Assistant Director of Pharmacy for
More information6/13/2012. Cardiovascular Disease Prevention in Women: Update on the 2011 American Heart Association Guidelines. Your Institution Here.
Your Institution Here Objectives Cardiovascular Disease Prevention in Women: Update on the 2011 American Heart Association Guidelines Discuss strategies to assess and stratify women into high risk, at
More informationDyslipidemia in women: Who should be treated and how?
Dyslipidemia in women: Who should be treated and how? Lale Tokgozoglu, MD, FACC, FESC Professor of Cardiology Hacettepe University Faculty of Medicine Ankara, Turkey. Cause of Death in Women: European
More informationRisk Factors and Primary and Secondary Prevention of Coronary Heart Disease
Special Issue Risk Factors and Primary and Secondary Prevention of Coronary Heart Disease Shung Chull Chae, M.D. Department of Internal Medicine / Division of Cardiology Kyungpook National University College
More informationPIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationPresenter Disclosure Information
Prediabetes & Type 2 Diabetes Prevention Cari Ritter, PA-C Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More informationQué factores de riesgo lipídicos debemos controlar? En qué medida?
Qué factores de riesgo lipídicos debemos controlar? En qué medida? Risk category High risk: CHD or CHD risk equivalents (10- year risk >20%) Moderately high risk: two or more risk factors (10-year risk
More informationFinancial Conflicts of Interest
Hormone Treatment of Menopausal Women: What Are the Data Telling Us (and Not Telling Us)? S. Mitchell Harman, M.D., Ph.D. Chief, Endocrine Division Phoenix VA Health Care System Clinical Professor, Medicine
More informationWomen and Coronary Artery Disease. Aren t Women Just Like Men?
Women and Coronary Artery Disease Aren t Women Just Like Men? Anita Wokhlu, MD Assistant Professor of Medicine UF Shands Gainesville, FL Wed Feb 1, 2017 CP1310268-1 Disclosure Of Relationships Anita Wokhlu,
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationHDL-C. J Jpn Coll Angiol, 2008, 48: NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart
Online publication March 25, 2009 48 6 2007 2007 HDL-C LDL-C HDL-C J Jpn Coll Angiol, 2008, 48: 463 470 NIPPON DATA80, MEGA study, JELIS, dyslipidemia, risk assessment chart 1987 NIPPON DATA80 Iso 10 MRFIT
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationYour Name & Phone Number Here! Longevity Index
Your Name & Phone Number Here! Longevity Index Your Health Risk Analysis is based on a variety of medical and scientific data from organizations such as the American Heart Association, American Dietetic
More informationWomen and Heart Disease
Women and Heart Disease The Very Latest in Cardiovascular Medicine and Surgery Gretchen L. Wells, MD, PhD, FACC Thomas Whayne Endowed Professor in Women s Heart Health Gill Heart Institute University of
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationUnderstanding Cholesterol and Triglycerides
MINTO PREVENTION & REHABILITATION CENTRE CENTRE DE PREVENTION ET DE READAPTATION MINTO Understanding Cholesterol and Triglycerides About This Kit Along with cigarette smoking, high blood pressure, physical
More informationCardiovascular Risk Assessment and Management Making a Difference
Cardiovascular Risk Assessment and Management Making a Difference Norman Sharpe March 2014 Numbers and age-standardised mortality rates from all causes, by sex, 1950 2010 Death rates halved Life expectancy
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationThe Latest Generation of Clinical
The Latest Generation of Clinical Guidelines: HTN and HLD Dave Brackett Clinical Guideline Purpose Uniform approach Awareness of key details Diagnosis Treatment Monitoring Evidence based approach Inform
More informationJanet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode Island Cardiology Center
Primary and Secondary Prevention of Coronary Artery Disease: What is the role of non statin drugs (fenofibrates, fish oil, niacin, folate and vitamins)? Janet B. Long, MSN, ACNP, CLS, FAHA, FNLA Rhode
More informationCLINICIAN INTERVIEW CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN
CARDIOVASCULAR DISEASE IN POSTMENOPAUSAL WOMEN Nanette K. Wenger, MD, is a recognized authority on women and coronary heart disease. She chaired the US National Heart, Lung, and Blood Institute conference
More information